CSF level of beta-amyloid peptide predicts mortality in Alzheimer's disease by Boumenir, A et al.
RESEARCH Open Access
CSF level of β-amyloid peptide predicts
mortality in Alzheimer’s disease
Adla Boumenir1, Emmanuel Cognat1, Severine Sabia2, Claire Hourregue1, Matthieu Lilamand1, Aline Dugravot2,
Elodie Bouaziz-Amar3, Jean-Louis Laplanche3, Jacques Hugon1, Archana Singh-Manoux2,4, Claire Paquet1 and
Julien Dumurgier1,2*
Abstract
Objective: Alzheimer’s disease (AD) is the sixth leading cause of death, with an average survival estimated between
5 and 10 years after diagnosis. Despite recent advances in diagnostic criteria of AD, few studies have used biomarker-
based diagnostics to determine the prognostic factors of AD. We investigate predictors of death and institutionalization
in a population of AD patients with high probability of AD physiopathology process assessed by positivity of three CSF
biomarkers.
Methods: Three hundred twenty-one AD patients with abnormal values for CSF beta-amyloid peptide (Aβ42), tau, and
phosphorylated tau levels were recruited from a memory clinic-based registry between 2008 and 2017 (Lariboisiere
hospital, Paris, France) and followed during a median period of 3.9 years. We used multivariable Cox models to estimate
the hazard ratio (HR) of death and institutionalization for baseline clinical data, genotype of the apolipoprotein E (APOE),
and levels of CSF biomarkers.
Results: A total of 71 (22%) patients were institutionalized and 57 (18%) died during the follow-up. Greater age, male sex,
lower MMSE score, and lower CSF Aβ42 level were associated with an increased risk of mortality. One standard deviation
lower CSF Aβ42 (135 pg/mL) was associated with a 89% increased risk of death (95% CI = 1.25–2.86; p = 0.002).
This association was not modified by age, sex, education, APOE ε4, and disease severity. There was no evidence
of an association of tau CSF biomarkers with mortality. None of the CSF biomarkers were associated with
institutionalization.
Conclusions: Lower CSF Aβ42 is a strong prognostic marker of mortality in AD patients, independently of age or
severity of the disease. Whether drugs targeting beta-amyloid peptide could have an effect on mortality of AD
patients should be investigated in future clinical trials.
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Background
Patients with Alzheimer’s disease (AD) have a reduced life
expectancy compared to the general population, with an
average survival estimated between 5 and 10 years after
diagnosis [1–3]. AD is currently the sixth leading cause of
death [4], and its contribution to mortality is thought to be
underestimated due to under-diagnoses of AD [5] and is
likely to increase rapidly due to the population aging and
the resulting increase in number of persons with AD [6].
The determinants of mortality in AD patients remain
unclear; age of the patient and severity of the disease
have been shown to be important [2, 7, 8]. An important
limitation is the use of clinical criteria for AD diagnosis
due to their poor specificity, estimated to be lower than
70% [9]; these criteria do not allow various other causes of
cognitive impairment (vascular dementia, Lewy body
disease, psychiatric disorders, etc.) to be ruled. The use of
tau and β-amyloid peptide (Aβ) biomarkers in diagnostic
criteria to reflect the hallmarks of AD neuropathology, and
their progressive generalization in clinical setting, allows
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more accurate diagnosis of AD [10]. These biomarkers
have now been incorporated in research diagnostic criteria
proposed by the National Institute on Aging and Alzhei-
mer’s Association (NIA-AA) [11], and the International
Working Group [12]. More recently, a “biological defin-
ition” of AD has been proposed, the A/T/N classification
which uses biomarkers of β-amyloid pathology (A), tau
lesions (T), and neurodegeneration markers (N) [13, 14].
Despite advances in diagnostic criteria of AD, few studies
have used these biomarker-based diagnostics to determine
the prognostic factors of AD. Accordingly, the aim of the
present study is to investigate the prognostic value of base-
line clinical data, ε4 allele of the apolipoprotein E (APOE)
gene, and CSF biomarkers as determinants of mortality
and institutionalization in persons diagnosed with AD. To
ensure homogeneity in the population of patients, we re-
stricted the analysis to patients with a clear CSF biomarker
profile, i.e., abnormal values for all three CSF biomarkers
(Aβ42, total tau, phosphorylated tau (p-tau 181)), corre-
sponding to the recently proposed A+T+N+ profile [13].
Methods
Study population
Patients were recruited from a memory clinic-based regis-
try (the BioCogBank study, Lariboisiere hospital, Paris,
France) [15]. All patients included in this registry under-
went an assessment of CSF AD biomarkers between 2008
and 2017 to explore a cognitive disorder. Subjects were
selected for the present study if they were diagnosed with
probable AD according to the NIA-AA criteria [11], had
data on APOE genotype, and if CSF Aβ42 level was below
cut-off and CSF tau and p-tau 181 above the cut-off (A+T
+N+ profile). Level of education (low: primary school or
less, intermediate: secondary to high school, high:
baccalaureate or university degree) was recorded, as well as
the age at the first consultation. Severity of disease was
assessed using the Mini-Mental Status Examination
(MMSE) score at the time of lumbar puncture.
CSF analysis
Lumbar puncture was performed on patients in a fasting
state, typically between 9 and 12 in the morning. CSF was
collected in 10-mL polypropylene tubes (January 2008 to
November 2012: CML model TC10PCS; December 2012
to 2018: Sarstedt catalog no. 62.610.201). CSF samples
were centrifuged at 1000g for 10min at 4 °C within 4 h of
collection and then aliquoted in 1.5mL polypropylene
tubes and stored at − 80 °C for further analysis (Eppendorf®
0030 120.086 EU). CSF levels of Aβ42, total tau, and
p-tau-181 were measured with the commercially available
sandwich ELISA INNOTEST®, using the manufacturer’s
procedures (Fujirebio Europe NV, formely Innogenetics
NV). CSF levels of Aβ40 were only assessed systematically
starting in September 2012, using ELISA INNOTEST®
from Fujirebio.
Cut-offs were those used in clinical setting, determined
as the optimal cut points (e.g., using the Youden index) to
differentiate clinically diagnosed AD patients from other
disorders and cognitively normal controls [16, 17]. As the
type of the polypropylene tube changed in November
2012, cut-offs were adjusted after this date. The cut-offs
for CSF Aβ42, tau, and p-tau 181 moved from 500/300/
65 pg/mL to 730/300/58 pg/mL after the change in tube is
used. The Alzheimer’s Association quality control pro-
gram for CSF biomarkers validated the quality of CSF
evaluations of the hospital biochemistry department [18].
Outcomes measures
Vital status and institutionalization on June 1, 2018, were
determined for each participant. When the patient could
not be reached directly, we contacted their relatives or
personal physicians to determine their status. Date of
institutionalization and/or death was recorded; the cause
of death was not available.
APOE genotyping
Venous blood was drawn from participants after informed
consent. Genomic DNA was extracted from 200 μL of
frozen blood using automated procedures and dedicated
DNA purification kits (Maxwell 16, Promega, Madison,
WI, USA). After amplification of exon 4 of the APOE gene,
the APOE allelic patterns were identified using denaturing
high-performance liquid chromatography (WAVE DNA
fragment analysis system, Transgenomic, Omaha, NE,
USA) with appropriate controls using the method
described previously [19].
Statistical analyses
Participant characteristics were presented overall, accord-
ing to their APOE ε4 allele status (none ε4, one ε4, two ε4)
and their outcome status at the end of the follow-up
(death yes/no, institutionalization yes/no). Proportions
were calculated for categorical variables, while means and
standard deviations were computed for continuous vari-
ables. Normality of the distributions of the continuous var-
iables was checked using Shapiro-Wilk test, and CSF Aβ42
was the only variable to be normally distributed. Statistical
significance was assessed using a χ2 test or Student t test
(CSF Aβ42) or Wilcoxon-Mann-Whitney test (other
continuous variables) as appropriate.
Follow-up for mortality and institutionalization was
defined as the time between the first consultation at the
memory clinic and date of death/institutionalization or
the end of follow-up (January 1, 2018), whichever came
first. As univariate analyses showed levels of CSF Aβ42
to be lower in patients who died or were institutional-
ized during the follow-up, we calculated the cumulative
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incidence of survival and being free of institutionalization
as a function of tertiles of CSF Aβ42 using the
Kaplan-Meier method and compared them with the log
rank test. As the nature of the polypropylene tube has a
strong influence on CSF Aβ42 measurement [16], tertiles
of CSF Aβ42 were specific for the collection tube used
(before and after November 2012). In further analyses, we
checked that use of quartiles or quintiles instead of tertiles
of CSF Aβ42 led to similar findings. We then used Cox
proportional hazard models to estimate hazard ratios for
death and institutionalization. The proportional hazards
assumptions were checked by computing Schoenfeld re-
siduals. We used tests of interaction to assess whether ob-
served associations were robust across age, sex, education,
APOE ε4, and disease severity (MMSE). The following pa-
rameters were included in the multivariable Cox model:
age, sex, MMSE, level of education, APOE ε4 status, col-
lection tube for CSF, CSF Aβ42, and CSF tau.
Age, MMSE, and levels of CSF biomarkers were stan-
dardized to z-scores (mean = 0, SD = 1) to estimate haz-
ard ratios in order to allow comparisons of the strength
of associations of different markers with mortality and
institutionalization. The use of z-scores as continuous
variables ensured that specific thresholds used to
categorize predictors did not drive the results. Stratified
analyses were performed to assess the association be-
tween CSF Aβ42 and mortality in different subgroups
defined by sex, median age, level of education, tertiles of
MMSE, and APOE ε4 status. Analyses were also
stratified by the type of tube used for collection of CSF
(before and after November 2012) to ensure that results
were not affected by modality of collection of CSF Aβ42.
CSF tau and CSF phosphorylated tau were highly corre-
lated in our sample leading us to use CSF tau in the
main analyses; use of CSF p-tau 181 instead of CSF tau
led to similar findings and conclusions.
All resulting p values were two-tailed, and p ≤ 0.05 was
considered statistically significant. Statistical analyses
were performed using SAS version 9.3 (SAS Institute,
Cary, NC, USA).
Results
Between 2008 and 2017, 1068 patients underwent CSF
biomarker assessment for possible cognitive disorders in
our memory clinic (flow-chart presented in Fig. 1).
Among them, 382 patients (35.8%) had a diagnosis of
AD with an A+T+N+ CSF biomarker profile. Thirty-six
patients were excluded due to missing data for APOE
genotype, and 25 patients were lost of follow-up and
their mortality/institutionalization status could not be
determined. A total of 321 patients were included in the
analysis; no differences in age, sex, MMSE, or bio-
markers levels were observed between included and
non-included patients (Table 1). Subsequent analyses
were based on 321 persons, corresponding to a
follow-up of 1243 person-years. Among them, 71 pa-
tients (22%) were institutionalized and 57 patients (18%)
died during a median of follow-up of 3.9 years.
Fig. 1 Flow-chart of the study. Selection of the patients for the analyses
Boumenir et al. Alzheimer's Research & Therapy           (2019) 11:29 Page 3 of 9
Baseline characteristics of the population overall and as
a function of the APOE ε4 genotype are summarized in
Table 2. The mean (SD) age at baseline was 71.0 (8.5)
years, 62% were women, 61% were carrying at least one
APOE ε4 allele, and the mean (SD) MMSE score was 20.3
(5.8). The APOE ε4 alleles were associated only with CSF
Aβ42 where the mean was lower in AD patients with
homozygous ε4/ε4 compared to other patients (Table 2).
Patients who died during the follow-up were older, more
often men, had lower baseline MMSE scores, and had a
lower level of CSF Aβ42 compared to those who survived
(Table 3). Patients who were institutionalized had a lower
MMSE score and a lower level of CSF Aβ42 compared to
those who were not institutionalized. No differences for ei-
ther outcome were observed for CSF tau or CSF p-tau 181.
Figure 2 shows the Kaplan-Meier curves for mortality
and institutionalization by tertiles of CSF Aβ42. As no
differences were observed for the 2d and 3d tertiles, they
were combined and compared to the lowest tertile.
Kaplan-Meier curves for mortality began to separate 24
months after baseline assessment and continued to di-
verge afterwards. After 100 months of follow-up, 35% of
the patients in the lower tertile of CSF Aβ42 were still
alive, versus 62% for those in the top 2 tertiles (P for log
rank = 0.029). When considering lower quartile (p =
0.031) or lower quintile (p = 0.030) instead of the lowest
tertile for CSF Aβ42, the findings were similar. We
observed no association between baseline CSF Aβ42 and
subsequent institutionalization (Fig. 2).
The multivariable Cox regression analyses for the risk of
death/institution are shown in Table 4. Higher age, male
sex, lower MMSE score, and lower CSF Aβ42 level were
associated with an increased risk of mortality. One stand-
ard deviation lower CSF Aβ42 was associated with 89%
increased risk of death (95% CI = 1.25–2.86; p = 0.002). In
this multivariate model, the association of 100 pg/mL
lower CSF Aβ42 with mortality was similar to the associ-
ation observed for 7.9 years greater age or 6.3 points lower
score on the MMSE. Men had two times higher risk of
death compared to women (HR [95% CI] = 2.11 [1.19–
3.76], p = 0.01). We observed no association of level of
education, APOE genotype, or level of CSF tau with mor-
tality. When considering the amyloid ratio (Aβ42/40) in
the multivariable model, an association with mortality was
also observed. One standard deviation lower amyloid ratio
was associated with a twice higher risk of death over the
follow-up (HR [95% CI] = 2.10 [1.01–4.39], p = 0.04).
The predictors had a less robust association with risk
of institutionalization; intermediate level of education
and lower baseline MMSE score were associated with in-
creased risk of institutionalization. Men tended to be at
higher risk than women (HR [95% CI] = 1.56 [0.94–
2.59), p = 0.09). We found no effect of APOE genotype
or CSF biomarkers on the risk of institutionalization.
Figure 3 presents the results of stratified analyses for
the risk of death as a function of one standard deviation
decrease in CSF Aβ42; there was no robust evidence of
difference in associations in the subgroups. Reassuringly,
the type of tube used to collect CSF data (before and
after November 2012) did not influence the association
between CSF Aβ42 level and mortality.
Discussion
In this study, including 321 AD patients, with verifica-
tion of AD physiopathology using positivity of the three
widely used CSF biomarkers, we found that lower levels
of CSF Aβ42 to be associated with an increased risk of
death. This association was clinically significant as the
effect of 100 ng/mL lower CSF Aβ42 on mortality was
similar to that of 8 years of aging. We show the main ef-
fects of previously known risk factors such as age, male
sex, and severity of the disease to be similar to those in
other studies, providing evidence of the robustness of
our results. There was also evidence of the importance
of the amyloid ratio (Aβ42/40) for mortality. We found
no association between APOE genotype and tau bio-
markers on mortality outcomes in AD patients. The risk
of institutionalization in AD patients was associated with
poorer MMSE scores, used here as a proxy for severity
of AD, but CSF biomarkers, APOE genotype, and age
were not associated with risk of institutionalization.
Table 1 Comparison between AD patients (A+T+N+ classification)
who were included and not included in the analyses due to
missing data
Characteristics AD patients with A+T+N+ profile
Included Not included
(N = 321) (N = 61) P value
Age, year, mean (SD) 71.0 (8.5) 71.3 (8.1) 0.68
Women, n (%) 200 (62.3) 37 (59.7) 0.70
MMSE, mean (SD) 20.3 (5.8) 20.3 (6.7) 0.85
Level of education, n (%)a
Low 106 (35.8) 15 (31.9)
Intermediate 110 (36.8) 11 (23.4)
High 81 (27.4) 21 (44.7) 0.04
CSF biomarkers, pg/mL, mean (SD)
Aβ42 483.8 (134.8) 471.8 (133.7) 0.52
Aβ40b 13,345 (5447) 13,323 (4812) 0.92
Ratio Aβ42/40b 0.047 (0.022) 0.044 (0.017) 0.57
Tau 684.9 (276.9) 671.8 (285.9) 0.72
p-Tau 181 102.6 (39.0) 100.9 (39.5) 0.73
A+T+N+ profile: Abnormal values for three CSF biomarkers (Aβ42, total tau,
phosphorylated tau (p-tau 181))
AD Alzheimer’s disease, SD standard deviation
aLow: primary school or less, intermediate: secondary to high school, high:
baccalaureate or university degree
bCSF Aβ40 was available for 255 patients
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Table 2 Baseline characteristics of the study population, overall, and stratified by APOE ε4 genotype
Characteristics APOE genotype
AD patients 0 ε4 1 ε4 2 ε4
(N = 321) (N = 125) (N = 141) (N = 55) P value
Age, year, mean (SD) 71.0 (8.5) 71.4 (9.9) 71.4 (7.6) 69.0 (6.9) 0.07
Women, n (%) 200 (62.3) 76 (60.8) 87 (61.7) 37 (67.3) 0.70
MMSE, mean (SD) 20.3 (5.8) 20.4 (5.6) 19.8 (5.9) 21.4 (5.8) 0.16
Level of education, n (%)
Low 106 (35.7) 48 (40.3) 44 (33.9) 14 (29.2)
Intermediate 110 (37.0) 38 (31.9) 50 (38.5) 22 (45.8)
High 81 (27.3) 33 (27.7) 36 (27.7) 12 (25) 0.49
APOE ε4 carriers, n (%) 196 (61.1) – – – –
Years of follow-up, mean (SD) 3.9 (2.4) 3.8 (2.5) 3.8 (2.4) 4.1 (2.6) 0.74
Death, n (%) 57 (17.8) 25 (20.0) 24 (17.0) 8 (14.6) 0.65
Institution, n (%) 71 (22.1) 26 (20.8) 35 (24.8) 10 (18.2) 0.54
CSF biomarkers, pg/mL, mean (SD)
Aβ42 483.8 (134.8) 481.9 (136.1) 512.1 (126.1) 415.9 (130.8) < 0.001
Aβ40b 13,298 (5454) 12,820 (5648) 13,843 (5498) 12,928 (4897) 0.19
Ratio Aβ42/40b 0.047 (0.022) 0.049 (0.022) 0.047 (0.024) 0.040 (0.014) 0.08
Tau 684.9 (276.9) 677.4 (271.4) 705.2 (291.9) 649.5 (248.1) 0.61
p-Tau 181 102.6 (39.0) 103.6 (46.4) 103.8 (35.0) 97.4 (29.6) 0.60
aLow: primary school or less, intermediate: secondary to high school, high: baccalaureate or university degree
bCSF Aβ40 was available for 214 patients
Table 3 Characteristics associated with death and institutionalization during the follow-up
Characteristics Death Institutionalization
No Yes No Yes
(N = 264) (N = 57) P value (N = 250) (N = 71) P value
Age, year, mean (SD) 70.4 (8.2) 73.8 (9.3) 0.001 71.0 (8.2) 70.9 (9.5) 0.89
Women, n (%) 172 (65.2) 28 (49.1) 0.02 159 (63.6) 41 (57.8) 0.39
MMSE, mean (SD) 20.7 (5.6) 18.3 (6.6) 0.008 20.7 (5.9) 18.9 (5.5) 0.01
Level of education, n (%)
Low 82 (33.7) 24 (44.4) 86 (37.7) 20 (29.0)
Intermediate 92 (37.9) 18 (33.3) 77 (33.8) 33 (47.8)
High 69 (28.4) 12 (22.2) 0.32 65 (28.5) 16 (23.2) 0.10
APOE ε4, n (%)
0 100 (37.9) 25 (43.9) 99 (39.6) 26 (36.6)
1 117 (44.3) 24 (42.1) 106 (42.4) 35 (49.3)
2 47 (17.8) 8 (14.0) 0.65 45 (18.0) 10 (14.1) 0.54
CSF biomarkers, pg/mL, mean (SD)
Aβ42 505.9 (127.8) 381.6 (118.7) < 0.001 496.6 (135.9) 438.7 (121.3) 0.001
Aβ40b 13,284 (5362) 13,474 (6697) 0.51 13,195 (5351) 14,165 (6312) 0.36
Ratio Aβ42/40b 0.047 (0.022) 0.039 (0.013) 0.08 0.046 (0.019) 0.049 (0.038) 0.56
Tau 680.9 (273.0) 703.6 (296.2) 0.69 685.4 (280.0) 683.2 (267.5) 0.93
p-Tau 181 102.5 (41.0) 102.9 (28.3) 0.88 102.5 (39.5) 102.8 (37.4) 0.94
aLow: primary school or less, intermediate: secondary to high school, high: baccalaureate or university degree
bCSF Aβ40 was available for 214 patients
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Fig. 2 Kaplan-Meier estimates of the cumulative incidences of survival and free of institutionalization, according to lower tertile of CSF Aβ42
compared to the two higher tertiles. Cut-offs used for definition of lower tertile of CSF Aβ42: ≤ 336 ng/mL before November 2012, ≤ 494 ng/mL
after December 2012
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Table 4 Predictors of death and institution over the follow-up, multivariable Cox regression analyses
Characteristics Death Institutionalization
HR (95% CI) P value HR (95% CI) P value
Age, yeara 1.66 (1.21–2.28) 0.002 1.11 (0.86–1.44) 0.44
Men vs women 2.11 (1.19–3.76) 0.01 1.56 (0.94–2.59) 0.09
Level of educationb
Low Ref. – Ref. –
Intermediate 1.21 (0.58–2.52) 0.61 2.45 (1.25–4.83) 0.009
High 1.02 (0.45–2.31) 0.96 1.45 (0.68–3.09) 0.33
MMSE scorec 1.56 (1.16–2.10) 0.003 1.68 (1.29–2.18) < 0.001
APOE ε4 allele
0 Ref. – Ref. –
1 0.79 (0.43–1.44) 0.44 1.00 (0.58–1.73) 0.98
2 0.59 (0.25–1.36) 0.21 0.70 (0.32–1.52) 0.37
Collection tube, before 2012 vs recent 1.37 (0.60–3.01) 0.46 0.74 (0.36–1.52) 0.41
CSF Aβ42, pg/mLc 1.89 (1.25–2.86) 0.002 0.89 (0.60–1.32) 0.55
CSF tau, pg/mLa 1.11 (0.84–1.48) 0.45 0.99 (0.78–1.26) 0.96
aContinuous, estimate for 1 standard deviation increase
bLow: primary school or less, intermediate: secondary to high school, high: baccalaureate or university degree
cContinuous, estimate for 1 standard deviation decrease
Fig. 3 CSF Aβ42 and risk of death over follow-up: stratified analyses. Hazard ratios estimate relative risk of death for a decrease of one standard
deviation of CSF Aβ42, considered as a continuous variable. Models are adjusted for age, sex, education level, APOE genotype, type of collection
tube, MMSE, and CSF tau
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Few previous studies have examined whether AD bio-
markers are associated with prognostic outcomes such
as mortality and institutionalization, and to the best of
our knowledge, none have used biomarker-based criteria
for the ascertainment of AD status in order to ensure
homogeneity in the population of patients. A previous
study, based on 127 patients diagnosed with mild cogni-
tive impairment or dementia, found an association
between amyloid deposition assessed by amyloid PET
imaging and mortality; however, 37% of those included
in the analysis were negative for the amyloid marker
[20]. Another paper based on 196 AD patients reported
an association between CSF tau and mortality [20]. Here
again, 46% of these patients had at least one of the three
CSF biomarkers in the normal range. More recently, a
study on 616 AD patients, diagnosed according to clin-
ical and not biological criteria, failed to find an associ-
ation between CSF biomarkers and mortality [21].
Despite the association of APOE genotype with life ex-
pectancy [22], its association with mortality in AD pa-
tients remains unclear [23]. We found no significant
effect of APOE genotype on mortality, a finding that is
consistent with those of several other previous studies
[21, 24]. Homozygous ε4/ε4 patients tended even to have
a lower risk of dying during follow-up, which may be
partly explained by their younger age.
Several studies have shown an inverse association be-
tween CSF Aβ42 and total brain amyloid load, assessed by
neuropathology [25, 26] or by amyloid PET imaging [27,
28]. The association between lower CSF Aβ42, which re-
flects higher level of amyloid deposits in the brain, and in-
creased mortality may therefore be explained by more
advanced disease which contributes to risk of death. How-
ever, the association we found was not substantially atten-
uated by the adjustment for severity of AD as assessed by
the MMSE score, and we found no effect of CSF Aβ42 on
the risk of institutionalization. There is increasing
evidence of shared molecular mechanisms between AD
and atherosclerosis [29, 30], which would point towards
the role of Aβ peptide in vascular inflammation patho-
physiology [31, 32]. Plasmatic dosage of beta-amyloid pep-
tide has also shown to be associated with global [33] and
cardiovascular [34] mortality. It is possible that patients
with more pronounced brain amyloid pathology have a
higher risk of cardiovascular mortality. Several drugs
targeting Aβ peptide are currently being investigated in
on-going trials [35]. Beyond their hoped effect on the cog-
nition of patients, our results suggest also a hypothetical
positive effect on survival in AD patients. Interestingly, in
the negative solanezumab trial, the rate of cardiac disor-
ders at 18months tended to be lower in the treated group
compared to the placebo group (1.6% vs 2.9%, p = 0.06),
this was also the case for cerebrovascular accidents (0.0%
vs 0.5%, p = 0.06) [36].
This study has several strengths, including its large size,
a low rate of attrition over the follow-up, exclusive focus
on patients positive for all three CSF biomarkers, and the
fact that the analyses of CSF were performed in a single
biochemistry department which ensures that inter-site
variability does not affect results [16]. One of the limita-
tions is the lack of data on the exact cause of death which
precluded more detailed analyses on specific causes of
mortality. Another limitation is the variability in the meas-
urement of CSF Aβ42 which is likely to result in dilution
of the association. The recent development of automated
platforms for dosing AD biomarkers may in the future
contribute to decrease this variability.
Conclusions
In summary, we found in biomarker-positive AD pa-
tients that CSF Aβ42 rather than tau biomarkers is asso-
ciated with the risk of subsequent mortality. Whether
drugs targeting beta-amyloid peptide could have also an
effect on mortality of patients may deserve to be investi-
gated as an outcome in future clinical trials.
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